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Background: The HIV pandemic is characterized by extensive genetic variability, which has challenged the
development of HIV drugs and vaccines. Although HIV genomes have been classified into different types, groups,
subtypes and recombinants, a comprehensive study that maps HIV genome-wide diversity at the population level is
still lacking to date. This study aims to characterize HIV genomic diversity in large-scale sequence populations, and
to identify driving factors that shape HIV genome diversity.
Results: A total of 2996 full-length genomic sequences from 1705 patients infected with 16 major HIV groups,
subtypes and circulating recombinant forms (CRFs) were analyzed along with structural, immunological and peptide
inhibitor information. Average nucleotide diversity of HIV genomes was almost 50% between HIV-1 and HIV-2 types,
37.5% between HIV-1 groups, 14.7% between HIV-1 subtypes, 8.2% within individual HIV-1 subtypes and less than
1% within single patients. Along the HIV genome, diversity patterns and compositions of nucleotides and amino
acids were highly similar across different groups, subtypes and CRFs. Current HIV-derived peptide inhibitors were
predominantly derived from conserved, solvent accessible and intrinsically ordered structures in the HIV-1 subtype B
genome. We identified these conserved regions in Capsid, Nucleocapsid, Protease, Integrase, Reverse transcriptase,
Vpr and the GP41 N terminus as potential drug targets. In the analysis of factors that impact HIV-1 genomic
diversity, we focused on protein multimerization, immunological constraints and HIV-human protein interactions.
We found that amino acid diversity in monomeric proteins was higher than in multimeric proteins, and diversified
positions were preferably located within human CD4 T cell and antibody epitopes. Moreover, intrinsic disorder
regions in HIV-1 proteins coincided with high levels of amino acid diversity, facilitating a large number of
interactions between HIV-1 and human proteins.
Conclusions: This first large-scale analysis provided a detailed mapping of HIV genomic diversity and highlighted
drug-target regions conserved across different groups, subtypes and CRFs. Our findings suggest that, in addition to
the impact of protein multimerization and immune selective pressure on HIV-1 diversity, HIV-human protein
interactions are facilitated by high variability within intrinsically disordered structures.
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As the causative agent of AIDS, the Human Immunodefi-
ciency Virus (HIV) represents a worldwide threat to public
health and the economy. The HIV pandemic is character-
ized by extensive genomic diversity caused by multiple fac-
tors including multiple zoonotic transmissions into human
populations, high rates of viral evolution and recombination
[1]. HIV has two major types, HIV-1 and HIV-2, which are
further divided into groups, subtypes and recombinant
forms. Globally, over 90% of HIV infections belong to HIV-
1 group M viruses, which have been classified into 9
subtypes (A-D, F-H, J, K) and more than 50 circulating re-
combinant forms (CRFs) [1]. The high genetic diversity of
the HIV genome has challenged the development of drugs
and vaccines [2].
The HIV genome contains nine genes that encode fifteen
viral proteins (Additional file 1: Figure S1). Three major
genes, gag, pol and env, code for structural proteins (Matrix,
Capsid, Nucleocapsid, p6), enzymes (Protease, Reverse tran-
scriptase (RT), Integrase) and envelope proteins (GP120,
GP41), respectively. The remaining genes code for regula-
tory (Tat, Rev) and accessory proteins (Vif, Vpr, Vpu/Vpx,
Nef) [3]. These viral proteins can exhibit multiple functions
and interact with various human proteins during the viral
life cycle [4,5].
During the past three decades, many antiviral inhibitors
have been designed to prevent HIV replication by target-
ing different viral proteins [6]. These anti-HIV peptides
and small-molecule inhibitors either act by blocking active
sites of viral enzymes or interrupting protein interactions
[6]. For instance, the fusion inhibitor T20 (Enfuvirtide,
Fuzeon), a peptide derived from the GP41 heptad repeat
region, can efficiently inhibit viral entry by interrupting in-
teractions between the GP41 helices [7]. For all existing
drug classes, mutations in the HIV genome can cause drug
resistance [8]. Therefore, inhibitors have been preferen-
tially developed to target conserved regions of different
viral proteins [9]. HIV genetic diversity also challenges the
development of a global HIV vaccine [10]. While the vac-
cine trial STEP was unable to show preventive vaccination
in subtype B infected cohorts [11], the Thai trial RV144
showed for the first time that prime-boost vaccination
provided a modest efficacy in patients infected with
CRF01_AE [12]. For vaccine and drug design, it remainsTable 1 Information on HIV-1 and HIV-2 full-length genomic
Type
Group M
Subtype/CRF A1 B C D F1 G
Number of genomes 159 1425 554 65 25 27
Number of patients 134 657 429 57 22 23
Average length in nucleotides* 8500 8600 8600 8500 8500 8600
*: Only the HIV coding regions are counted.important to investigate the genomic diversity of different
HIV groups, subtypes and CRFs at a population level.
Despite a large body of knowledge on different aspects of
HIV pathogenesis, a large-scale analysis that reveals the
genome-wide diversity within and between different HIV
groups, subtypes and CRFs is still lacking. Although previ-
ous HIV genomic studies have reported subtype distribu-
tion, genetic variability, disease progression, evolutionary
rate, positive selective pressure and the origin of HIV
[11-27], most studies reported their findings using either
reference genomes or small cohorts of less than 100 pa-
tients or sequences in a single subtype. HIV-1 subtype B
which dominates infections in developed countries is the
most studied subtype, largely due to historical reasons [28].
For instance, the adaptive evolution during acute infection
was evaluated only in 11 individuals infected with HIV-1
subtype B [14]. In light of using HIV consensus sequences
as vaccine candidates, an analysis on the genetic difference
between consensus sequences and circulating strains was
limited to subtypes B and C using less than 100 sequences
[2], while other subtypes also prevail worldwide [29].
The last three decades have seen an accumulation of
HIV data including full-length genomic sequences, protein
crystal structures, HIV-human protein interactions, hu-
man T-cell epitope information and antiretroviral peptide
inhibitors derived from the HIV genome. By integrating
distinct but complementary sources of large-scale HIV
datasets, this study aims to characterize HIV genome-wide
diversity and to determine multiple factors that shape HIV
genomic diversity.
Results
Genome-wide diversity within and across HIV types,
major groups and subtypes
We quantified the nucleotide and amino acid diversity
of the HIV genome using 2996 full-length sequences
sampled from 1705 patients (Table 1). The amino acid
diversity was 53.8% (95% confidence interval (CI): 53.0-
54.6%) between HIV-1 and HIV-2, 41.1% (CI: 25.6-
54.3%) between HIV-1 groups, 18.0% (CI: 15.6-19.6%)
between HIV-1 subtypes, 12.0% (CI: 8.6-14.4%) within
HIV-1 subtypes and 1.1% (CI: 0.3-2.2%) within HIV-1
patients (Figure 1A). Similarly, nucleotide genomic di-
versity was found to be the highest when comparingsequence datasets
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Figure 1 Distribution of HIV genome-wide diversity and phylogenetic tree. (A) Distribution plots of amino acid diversity in the HIV genome. The
plots show the genomic diversity within HIV-1 infected patients (HIV-1 intra-patient, blue), within HIV-1 subtypes (HIV-1 intra-subtype, green), between
HIV-1 subtypes (HIV-1 inter-subtype, red), between HIV-1 group M and group N (HIV-1 inter-group, yellow), between HIV-1 group M and group O/P
(HIV-1 inter-group, black) and between HIV-1 and HIV-2 (pink). Distribution plots of nucleotide genomic diversity are shown in Additional file 1: Figure
S2. (B) Maximum likelihood phylogenetic tree of HIV groups and pure subtypes. Green cones indicate HIV-1 subtypes in group M, while orange cones
denote other HIV groups. All phylogenetic branches have bootstrap supports of more than 85% except one containing subtypes J, H and C. Branch
lengths from the root to HIV-1 and HIV-2 are shortened for visualization purposes. SIV strains were not included in our phylogenetic tree. Visualization
software: FigTree V1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/). (C) Distribution plots of amino acid diversity in 6 major HIV-1 subtypes and CRFs
(B, A1, C, D, CRF01_AE, CRF02_AG). X- and y-axes indicate the amino acid diversity and the proportions of sequence pairs, respectively. Six subplots in
the first and second rows show the intra-subtype amino acid diversity of 6 HIV-1 subtypes and CRFs. Three subplots in the third row show the
distribution of inter-subtype genomic diversity (B vs A1, B vs C, B vs 01_AE). One genomic sequence per patient (Table 1) was used for our analysis.
Distribution plots of the other inter-clade genomic diversity are shown in Additional file 1: Figure S3. (D) Average inter- and intra-clade genomic
diversity of HIV-1 and HIV-2. The top right matrix demonstrates results for amino acid diversity, the bottom left matrix for nucleotide diversity. HIV
subtypes and groups are shown on the left side of the matrix.
Li et al. Retrovirology  (2015) 12:18 Page 4 of 17HIV-1 and HIV-2 (mean: 48.32%, CI: 47.8-48.9%),
followed by HIV-1 inter-group (37.5%, CI: 26.0-45.7%),
HIV-1 inter-subtype (14.7%, CI: 12.2-15.8%), HIV-1
intra-subtype (8.2%, CI: 5.3-10.0%) and HIV-1 intra-
patient diversity (0.6%, CI: 0.2-1.4%) (Additional file 1:
Figure S2). As expected, the trend in HIV genomic di-
versity corresponds with the phylogenetic relationships
between groups and pure subtypes in HIV-1 and HIV-2
(Figure 1B).
We next quantified genomic diversity within and be-
tween individual HIV clades (Figure 1C, Additional file 1:
Figure S3). Within each HIV clade, amino acid diversity was
consistently higher than nucleotide diversity (Figure 1D).
CRF01_AE showed the lowest genomic diversity (nucleotide:
5.7%, amino acid: 8.7%) among the 10 HIV-1 subtypes with
at least 10 sequences available (Figure 1D). Sequence vari-
ability was not uniformly distributed along the full-length
HIV genome, but similar patterns were consistently ob-
served in HIV group, subtype and CRF genomes at the nu-
cleotide and amino acid levels (Figure 2A, B). Moreover, the
estimated geographical distribution of HIV-1 genomic di-
versity (Additional file 1: Figure S4) showed a good agree-
ment with the reported geographical distribution of HIV-1
subtypes [29].
Among all HIV proteins, Integrase was the most con-
served protein (mean ± deviation: 4.5 ± 1.1%), while GP120
varied the most (21.3 ± 2.5%) (Table 2). Pairwise compari-
sons of genetic diversity between subtype B and the other
clades identified conserved regions in the Capsid, Nucleo-
capsid, Protease, RT, Integrase, Vpr and the N terminus of
GP41 (Figure 2C). Despite the different degrees of sequence
diversity along the full-length genome, the nucleotide and
amino acid compositions were comparable across the 16
group and subtype genomes (Figure 3A, 3B).
Multiple factors shape HIV-1 genomic diversity
We next evaluated three potential factors (protein multi-
merization, immunological constraints, HIV-human pro-
tein interactions) that shaped the HIV genomic diversity.Firstly, we calculated the average diversity at amino acid
positions of the 15 HIV-1 proteins (Figure 3C). For every
HIV-1 group, subtype and CRF, the average amino acid di-
versity was significantly higher in the monomeric proteins
(Nucleocapsid, Vpr, Vpu, p6) than in the multimeric pro-
teins (Matrix, Capsid, Protease, RT, Integrase, Vif, Tat, Rev,
GP120, GP41, Nef) (p-value < 0.05) (Additional file 2:
Table S1). This suggests that protein multimerization im-
poses a constraint on the HIV-1 amino acid variability. Be-
sides our diversity analysis, we also measured synonymous
(dS) and non-synonymous (dN) substitution rates in the
HIV-1 subtype A1, B, C and CRF01_AE genomes, which
contained more than 100 sequences in our genomic data-
sets (Additional file 2: Table S2). Mann-Whitney U tests
were used to compare the distribution of dN, dS and the
ratio of non-synonymous to synonymous substitutions
(dN/dS) between the monomeric and multimeric protein
groups. We found that the distributions of dN/dS and
dN in these two groups were significantly different
(p-value < 0.05) in HIV-1 subtypes A1, B, C and
CRF01_AE (Additional file 2: Table S3). This suggests
that multimeric proteins are under the stronger negative
selective pressure than monomeric proteins.
Secondly, we evaluated the amino acid variation in the
known CD4 T cell, CD8 T cell and antibody epitopes
(see Materials). By measuring the diversity of 3066 amino
acid positions, we identified 919 (30%) variable positions
with amino acid diversity above 12.9% (the average amino
acid diversity within subtype B) using 657 subtype B gen-
omic sequences. Univariate analysis showed that these
variable positions were preferably located within antibody
epitopes (OR 1.43, CI: 1.15-1.79, Fisher’s exact test, p-
value = 0.0015) and CD4 T cell epitopes (OR 1.73, CI:
1.18-2.96, p-value = 0.0438), but not within CD8 T cell epi-
topes (OR 1.11, CI: 0.82-1.51, p-value = 0.498) (Figure 2A).
Thirdly, we mapped 1352 interactions between 1052
human and 15 HIV-1 proteins using the HIV-human
protein interaction dataset (Figure 3D, see Materials).
The following three observations support the hypothesis
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Figure 2 Plots of amino acid and nucleotide diversity in the HIV full-length genome. (A) Amino acid diversity along the HIV full-length genome
using the sliding windows (window size: 100AA; also see the plots of exact diversity values in Additional file 1: Figure S5). Each colored plot shows the
density of amino acid diversity for one HIV group, subtype or CRF genome, indicated by the figure legend. Six layers are shown beneath the plots: (1)
HIV-1 protein regions (HXB2 reference) are concatenated and shown with abbreviated names (e.g. MA: matrix); (2) peptide-inhibitor-derived region; (3)
CD8+ T cell epitope position; (4) CD4+ T cell epitope position; (5) antibody epitope position; (6) HIV-2 protein region (BEN reference). (B) Nucleotide
diversity along the full-length HIV genome using sliding windows (window size: 300 nucleotides; also see the plots of exact diversity values in
Additional file 1: Figure S6). Each colored plot shows the density of nucleotide diversity for one HIV group, subtype or CRF genome, indicated by the
figure legend. Annotated HIV-1 and HIV-2 reference genomes are shown beneath; each track contains one open reading frame (ORF). Long terminal
regions in the HIV genome are not shown. (C) Contour map of inter-clade amino acid diversity between HIV-1 subtype B and the other HIV genomes.
Inter-clade amino acid diversity was calculated by a sliding window of 30 amino acids over the HIV genome (low: ≤1 AA difference, high: ≥25 AA
differences). Five colored layers beneath the contour map are annotated similarly in (A).
Li et al. Retrovirology  (2015) 12:18 Page 6 of 17that the amino acid diversity of HIV-1 proteins is asso-
ciated with HIV-human protein interactions. (1) Univar-
iate analysis showed that HIV-1 proteins with higher
amino acid diversity interact with more human proteins
(Pearson’s coefficient = 0.74, p-value = 0.0017). Polyno-
mial regression analysis further identified a second-
order model that fitted the correlation between these
two variables (Figure 4A, adjusted R-squared: 0.82). (2)
Intrinsically disordered structures in HIV-1 proteins can
interact with multiple interaction partners [30]. Univari-
ate analysis showed a significant correlation between
the average amino acid diversity and the average dis-
order scores of HIV-1 proteins (Pearson’s coefficient =
0.64, p-value = 0.015, Figure 4B). (3) The levels of HIV-
human protein interactions clustered according to the
functional roles of the HIV-1 proteins, which have dif-
ferent functional roles and requirements for interactions
with human proteins (Figure 4C). HIV regulatory pro-
teins (Tat, Rev) and envelope proteins (GP120, GP41)
had the largest number of interactions with different
human proteins (568 for the regulatory proteins, 322 forTable 2 Average amino acid diversity of viral proteins within
Clade # MA CA NC p6 PR RT IN
HIV-1 Subtype A1 13.07 7.3 7 19.89 5.59 6.44 4.76
Subtype B 12.92 4.95 10.83 14.99 8.21 6.04 4.91
Subtype C 16.11 5.77 9.39 15.52 6.15 5.84 4.45
Subtype D 14.78 5.08 10.85 13.16 7.68 6.98 4.80
Subtype F1 13.69 5.71 10.07 16.72 8.84 6.42 4.76
Subtype G 17.33 5.54 7.40 17.21 6.60 7.30 4.17
Subtype H 18.81 3.61 8.48 17.65 4.55 5.95 5.71
CRF01_AE 10.06 3.00 4.92 13.37 4.34 3.75 2.39
CRF02_AG 13.57 5.69 3.78 13.63 5.56 5.67 4.06
Group N 10.52 6.40 7.06 10.01 5.93 6.78 3.09
Group O 14.52 7.45 9.89 22.17 8.20 6.51 5.77
HIV-2 Group A 10.15 4.67 11.82 11.02 7.14 6.89 6.78
Group B 12.14 3.54 13.15 15.4 5.76 6.4 6.19
#: Only HIV groups, subtypes or CRFs with more than 2 genomic sequences are liste
*: Vpu in HIV-1 and Vpx in HIV-2.the envelope proteins), while viral enzymes had the least
number of interactions (Figure 4C). The average amino
acid diversity of envelope proteins (20.4%) and regula-
tory proteins (18.8%) was higher than that of accessory
proteins (16.0%), structural proteins (9.0%) and viral en-
zymes (5.9%) (Additional file 1: Figure S7). Our findings
suggest that HIV-1 proteins with higher genetic diver-
sities have larger intrinsically disordered structures and
interact with more human proteins.
Peptide inhibitors are mainly derived from conserved
subtype B genomic regions
We investigated the 121 HIV-derived peptide inhibitors re-
ported between 1993 and 2013 (Additional file 2: Table S4).
Figure 5A illustrates the GP41 structure and the GP41-
derived region of T20 as an example of HIV-derived pep-
tide inhibitors. Peptide inhibitors had on average a length
of 25 AAs (range: 3 to 73), a charge of +0.27 at pH 7.2 and
a molecular weight of 2953 g/mol. Most common amino
acids in these peptide inhibitors were leucine, glutamic acid
and isoleucine (Additional file 1: Figure S8). Comparisonsindividual HIV clades (%)
Vif Vpr Tat Rev Vpu/Vpx* GP120 GP41 Nef
13.63 9.86 18.14 16.83 23.04 23.34 13.38 14.64
14.71 11.29 19.32 18.34 20.04 23.93 15.59 17.79
10.61 10.64 15.37 16.10 20.21 22.89 14.19 14.96
11.57 11.74 17.89 15.87 19.40 23.58 13.61 14.42
11.04 9.26 17.01 15.70 18.27 20.24 13.39 14.02
14.36 10.33 15.51 18.39 19.25 23.87 12.98 14.15
15.46 9.11 19.28 19.80 18.31 21.51 12.33 16.34
9.32 7.97 13.57 13.34 12.80 17.40 9.62 11.78
13.44 7.70 13.58 15.49 16.42 23.37 12.09 15.45
11.02 4.87 12.15 12.77 35.01 21.43 9.15 12.64
16.17 12.16 21.61 21.25 27.12 28.65 19.35 17.96
12.74 22.55 22.59 22.75 10.40 18.55 16.47 21.98
12.71 12.66 20.44 15.82 11.45 21.20 15.29 20.59
d.
Amino acid diversity at individual HIV-1 proteins
GP41
90o
15%
20%
25%
30%
35%
40%
36.8%
22.2%
17.4%
23.7%
A
T
C
G
1%
2%
3%
4%
5%
6%
7%
8%
9%
A
R
N
D
C
Q
E
G
H
I
L
K
M
F
P
S
T
W
Y
V
Pr
op
or
tio
n
Pr
op
or
tio
n
B A1 C D F1 G H J K
01
AE
02
AG N O P A B
HIV-1 subtypes, CRFs and groups HIV-2 groups
B A1 C D F1 G H J K 01A
E
02
AG N O P A B
HIV-1 subtypes, CRFs and groups HIV-2 groups
A B
C D
Pr
op
or
tio
n
Figure 3 (See legend on next page.)
Li et al. Retrovirology  (2015) 12:18 Page 7 of 17
(See figure on previous page.)
Figure 3 Nucleotide and amino acid composition of HIV genomes and 3D mapping of HIV-human protein interactions. (A) Nucleotide
composition for HIV-1 and HIV-2. X-axis represents the HIV groups, subtypes and CRFs. Y-axis shows the average proportions of nucleotides (A, T, C, G)
using the HIV genomic sequence datasets (one sequence per patient, Table 1). (B) Amino acid composition for HIV-1 and HIV-2. X-axis represents HIV
groups, subtypes and CRFs. Y-axis shows the average proportions of amino acids using the HIV protein sequence datasets (one sequence per patient,
Table 1). (C) Distribution plots of amino acid genetic diversity for 15 HIV-1 subtype B proteins. Each subplot demonstrates a viral protein. X- and y-axes
indicate the amino acid diversity and the proportions of amino acid diversity, respectively. Red lines inside the distribution plots indicate the mean
values of amino acid diversity at individual proteins. (D) Top and side views of 3D HIV-human protein interaction networks. HIV-1 proteins with protein
names annotated are indicated by green spheres. Human proteins that interact with only one HIV-1 protein are indicated by blue spheres in the outer
circle (one human protein one sphere). Human proteins that interact with more than one HIV-1 protein are indicated by purple spheres above the
plane of HIV-1 proteins. The height of the layers above the plane indicates the number of HIV proteins that a human protein interacts with. Below,
human proteins are clustered if they interact with a set of more than one HIV-1 protein. Abbreviation names have been described in the abbreviation
list. Visualization software: Geomi V2.0(http://sydney.edu.au/engineering/it/~visual/geomi2/).
Li et al. Retrovirology  (2015) 12:18 Page 8 of 17between the 121 peptide sequences and the consensus se-
quences of 16 HIV group, subtype and CRF genomes
showed the highest sequence similarity with subtype B
(79.8%) (Figure 5B). Aspartic acid to asparagine (25.7%)
was the most common amino acid substitution between
the consensus subtype B sequence and the peptide inhibitor
sequences (Figure 5C).
We characterized peptide-derived regions in the subtype
B genome. Of the 894 amino acid positions from which the
121 peptide inhibitors were derived, 41.2% were located in
helix structures and 60.2% displayed less than 5% genetic di-
versity in the subtype B genome. Forty-two inhibitors had
IC50 or EC50 values less than 1 μM and were derived from
249 amino acid positions in the HIV-1 genome (Additional
file 2: Table S4). In the subtype B genome, these 249 posi-
tions displayed significantly lower amino acid diversity com-
pared to the genome-wide diversity (Figure 5D, 10.1% vs
12.9%, p-value = 0.019), and were likely to be from
conserved (amino acid diversity < 5%, OR: 1.43 (1.09-1.88),
p-value = 0.016), solvent exposed (OR: 2.47 (1.88-3.24), p-
value = 3.9E-11) and intrinsically ordered structures (dis-
order score < 0.4, OR: 1.75 (1.21-2.51), p-value = 0.0019)
(Figure 5E).
Integrated findings from our analyses on HIV-1 gen-
omic diversity, HIV-derived peptide inhibitors and pro-
tein structures are visualized in Figure 6. The HIV
genomic sequence datasets and our toolbox developed
for data visualization, genomic diversity analysis and
HIV genomic alignments are freely available in Additional
file 3.Discussion and conclusions
To our knowledge, this study provides the first large-scale
analysis that investigates the genomic variability of 16 major
groups, subtypes and CRFs in HIV-1 and HIV-2. While
previous studies have reported the diversity of HIV ge-
nomes in small cohorts of patients (n < 250) [11-24,31], our
analyses evaluated HIV genome-wide diversity using 2996
full-length genomic sequences sampled from 1705 patientsworldwide. We evaluated three important aspects of HIV
genomic diversity using the integrated datasets of genomic
sequences, protein structures, HIV-human protein interac-
tions, human immune epitopes and HIV-derived peptide
inhibitors. Firstly, we quantified HIV genomic diversity at
the individual and population levels. Secondly, we reported
possible associations between HIV-1 amino acid diversity
and protein multimerization, immunological constraints
and HIV-human protein interactions. Thirdly, we mapped
conserved regions in the HIV genome and characterized
experimental and clinically used HIV-derived peptide inhib-
itors [7].Quantification of HIV genomic diversity
HIV-1 genomic diversity is the lowest within single
patients and increases in the following order when
different patients are considered: within subtypes, be-
tween subtypes, between groups and between HIV
types (Figure 1). A nucleotide genomic diversity was
quantified to be 48.3% between HIV-1 and HIV-2,
37.5% between HIV-1 groups, 14.7% between HIV-1
subtypes, 8.2% within HIV-1 subtypes, and 0.6% within
single patients infected with HIV-1. These results are in a
good agreement with previous studies which analyzed less
than 100 sequences [13,23]. Our study quantified genomic
diversity at the population level using the largest sequence
dataset ever analyzed, thereby resulting in robust and ac-
curate estimations.
As shown in Figure 2, the degree of HIV genetic diver-
sity varied along the full-length genome. A comparison
of the amino acid diversity of HIV proteins revealed the
highest diversity in the envelope proteins, followed by
the regulatory, accessory, structural and enzymatic pro-
teins (Figure 4, Table 2). Our diversity analysis showed
comparable results compared to our previous studies,
which reported the amino acid diversity of Gag and Rev
using 10862 and 4632 sequences respectively [9,32]. In
contrast, estimated amino acid diversities for Pol (5.7 ±
0.9%) and Env (18.7 ± 2.7%) displayed higher values than
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Figure 4 Correlations between HIV-1 protein diversity and HIV-human protein interactions, protein disorder and viral particle structures.
(A) Plot of polynomial regression between the HIV-1 protein diversity (x-axis) and the number of HIV-human protein interactions (y-axis). The second-order
model is Y ¼ 8346X2−1223X þ 57:96 (adjusted R-squared: 0.82, root-mean-square error: 42.31). (B) Plot of average protein disorder score and average
amino acid diversity in HIV-1 proteins. Red circles indicate the number of HIV-human protein interactions at individual viral proteins, for visualization purpose,
scaled between 20 and 200 interactions (proteins with fewer than 20 interactions are scaled to the same size as those with 20, proteins with more than 200
interactions are scaled to the same size as those with 200). Average amino acid diversities of HIV-1 proteins are calculated using subtype B sequences (one
genomic sequence per patient, Table 1). (C) Clustering of HIV-1 proteins and schematic view of HIV-1 viral particle. On the left, each colored circle represents
a viral protein positioned according to the clusters of protein functions. The size of each red circle indicates the number of HIV-human protein interactions
involving each HIV-1 protein (see (B)). On the right, the schematic view of mature viral particle is visualized at the bottom with annotations indicated in the
inserted figure legend. Above, surface representations show the structures of HIV-1 proteins that are grouped according to their functional roles. Different
units in HIV-1 multimeric proteins are indicated with different colors and HIV-1 monomeric proteins are colored pink. HIV-1 protein structures are scaled
according to their precise protein sizes for direct comparison. Visualization software: PyMOL V1.5 (http://www.pymol.org/).
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subtypes A and B [24]. Using large-scale sequence data-
sets, our study thus provides a complete estimation of
the genetic diversity in 16 HIV proteins.HIV genomic diversity is shaped by multiple factors
HIV genomic diversity is driven by the high rates of viral
replication, recombination and mutation [33], but other
factors also play a role in shaping HIV genomic diversity.
For instance, positive selection was significantly identified
in the overlapping reading frames of the HIV-1 subtype B
genome, probably due to functional and structural
requirements [26]. To evaluate other potential factors,
we correlated HIV amino acid diversity with protein
multimerization, human immunological constraints and
HIV-human protein interactions. We showed that CD4
T cell and antibody epitope positions in the HIV-1 gen-
ome were likely to have high amino acid diversities, sup-
porting the hypothesis that the human immune system
imposes a diversifying selective pressure on the HIV-1
genome [26]. Moreover, we found that the average
amino acid diversity was significantly lower in the mul-
timeric than in the monomeric proteins, suggesting that
protein multimerization places a constraint on HIV-1
sequence conservation. While synonymous substitution
rates were not significantly different, nonsynonymous
substitution rates were significantly lower in multimeric
proteins (Additional file 2: Table S3), suggesting that the
negative selective pressure may be stronger for multi-
meric proteins. Previous findings on other protein fam-
ilies have also shown that multimeric proteins are
relatively conserved and have less tolerance for amino
acid substitutions, probably because of the structural
and functional constraints [34-37].
We mapped 1352 HIV-human protein interactions be-
tween 15 HIV-1 proteins and 1052 human proteins. A
strong association was found between the amino acid di-
versity of HIV-1 proteins and the number of HIV-human
protein interactions (Figure 4A). HIV-1 proteins with
higher genetic diversities tended to interact with morehuman proteins. This is probably associated with structur-
ally disordered regions in HIV-1 proteins (Figure 4B),
which provide the structural flexibility for HIV to interact
with multiple human proteins [30]. For instance, GP120
uses five hypervariable loops (Additional file 1: Figure
S12) to interact with various human proteins [38]. An in-
tricate landscape of HIV-human protein complexes is
made by HIV to exploit human cellular machineries dur-
ing the HIV infection and production [39]. Despite the
high variability of HIV, it is surprising that the nucleotide
and amino acid compositions were remarkably constant
across all HIV-1 and HIV-2 clades (Figure 3A, 3B), sug-
gesting that other constraints may be active to restrict the
HIV genetic diversity [25]. For instance, HIV RNA struc-
tures require the stable nucleotide compositions for the
reverse transcription [25].Conserved drug targets in the HIV-1 genome
Many peptide inhibitors derived from HIV-1 proteins have
shown promising antiviral activities and some of these in-
hibitors are currently under clinical trials [40,41]. Our study
summarized HIV-derived peptide inhibitors published be-
tween 1993 and 2013 (Additional file 1: Figure S12-S21,
Additional file 2: Table S4), and mapped the positions of
these inhibitors to the HIV-1 genome (Figure 6). We
showed that most peptide inhibitors were derived from the
regions of HIV-1 subtype B proteins (Figure 5B), which had
conserved, solvent exposed and intrinsically ordered struc-
tures (Figure 5E). This information enhances current un-
derstanding of HIV-derived peptide inhibitors, which may
provide valuable guidelines for the design of novel peptide
inhibitors [42,43].
In the full-length genome, we identified conserved regions
in Capsid, Nucleocapsid, Protease, RT, Integrase, Vpr and
N-terminal domain of GP41 (Figure 2). These conserved
regions have been targeted by known anti-HIV inhibitors
(Figure 6). For instance, over 40 experimental inhibitors with
promising antiviral activities have been designed to target
Capsid and Nucleocapsid [9]. HIV enzymes (Protease, RT,
Integrase) are targeted by the majority of the FDA-approved
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Figure 5 Characterization of HIV-derived peptide inhibitors. (A) Cartoon representation of GP41 structure. The red structure indicates the
region from which peptide inhibitor T20 was derived (PDB: 3H01). (B) Bar plot of sequence similarities between peptide inhibitor sequences and
the sequences of HIV-derived regions in the consensus genome of different HIV clades. X-axis presents the HIV groups, subtypes and CRFs. Y-axis
shows the sequence similarity between peptide inhibitor sequences and the sequences of HIV-derived regions in the consensus genomes of HIV
groups, subtypes or CRFs. (C) Amino acid replacements between peptide inhibitor sequences and HIV-derived regions in the subtype B genome.
The percentage values (%) are colored using heat maps. (D) Distribution (bee-swarm) plots of amino acid diversity in the full-length subtype B
genome (black crosses), peptide-derived regions (blue diamonds) and peptide-derived regions of those inhibitors whose IC50/EC50 are less than
1 μM (red circles). Each shape represents the amino acid diversity at one protein position. Two-sample Kolmogorov-Smirnov tests were performed
to compare diversity distributions (significance level: 0.05). (E) Plot of amino acid diversity (x-axis), disorder score (y-axis) and solvent accessible
surface area of peptide-inhibitor-derived regions (contour map, darker red indicates larger accessible surface areas). GP41 inhibitor T20 is also
annotated. For individual peptide inhibitors, the average amino acid diversity, disorder score and solvent accessible surface areas are shown in
Additional file 1: Figure S9, S10 and S11, respectively.
Li et al. Retrovirology  (2015) 12:18 Page 11 of 17antiretroviral drugs. Peptide inhibitor T20 targets the N-
terminal heptad domain of GP41 [44]. Overall, our sequence
analysis mapped the conserved drug target regions in the
HIV-1 genome, providing useful information for drug
design.Implications for HIV vaccine development
HIV subtype- and geography-specific vaccination has been
proposed to contend with the challenges imposed by the
high HIV genetic diversity [2]. Previous vaccine trials were
carried out in regional populations dominated by a single
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Figure 6 An integrated map of HIV-1 genomic diversity and protein structures. All 15 HIV-1 proteins are mapped in the circle with 8 layers,
showing the schematic view of HIV-1 peptide inhibitors (layer 1), protein secondary structures (layer 2, dark blue: helix structures, light blue:
beta-strand structures, white: random-coil structures), protein disorder scores (layer 3), amino acid diversity at individual positions (layer 4), human
CD4/CD8/antibody epitope regions (layer 5, three sub-layers from inside to outside represent CD8+ T cell, CD4+ T cell and antibody epitope
regions), HXB2 reference indices (layer 6), peptide-inhibitor-derived regions (layer 7) and the protein structures are colored according to the
diversity of amino acid positions (layer 8, low: 0%, high: ≥30%). Three major genes (gag, pol, env) are annotated in the center. Structures of
multimeric HIV-1 proteins are shown outside the circle and different protein units are colored separately. The list of PDB data is available in
Additional file 2: Table S5. Visualization software: Circos V0.64 (http://circos.ca/).
Li et al. Retrovirology  (2015) 12:18 Page 13 of 17HIV-1 subtype or CRF. For instance, the STEP [11] and
RV144 [12] vaccine trials targeted patient populations
mainly infected by subtype B and CRF01_AE, respectively.
Particularly, the RV144 trial in 2009 showed the first sign
that a prime–boost strategy achieved a modest vaccine
efficacy (31.2%) in the heterosexual population, which was
at risk for infections with CRF01_AE [12,31]. In our
analysis, CRF01_AE has the lowest genomic diversity
among the 12 analyzed HIV groups, subtypes and CRFs
(Figures 1D, 2A, 2B). It is thus tempting to speculate that
the low diversity of CRF01_AE may have contributed to
the success of the RV144 trial.
As conserved epitopes are ideal targets for potential vac-
cines to contend with the high HIV diversity [24,45], our
study highlighted position-specific conservation along the
full-length HIV genome (Figure 6). Moreover, HIV-1 con-
sensus sequences have been considered as potential vac-
cine candidates to minimize genetic diversity between
vaccine candidates and circulating strains [2]. Previous
analyses on fewer than 100 Matrix and GP160 sequences
reported that genetic diversity between subtype-specific
consensus sequences and circulating strains was only half
of the genetic diversity between circulating strains from
the same subtype [2]. We found that in the full-length
HIV genome, this effect was much smaller as we only ob-
served a 32.5% reduction of the genomic diversity (8.3%
vs. 12.3%, Additional file 1: Figure S22). As the most ex-
plored vaccine target protein, GP120 has the highest gen-
etic diversity among all HIV proteins (Table 2), presenting
a challenge in the search for broadly neutralizing anti-
bodies and vaccines [46]. Furthermore, we mapped the
global distribution of HIV-1 genomic diversity (Additional
file 1: Figure S4). Our results showed the highest HIV gen-
omic diversity in Central Africa, the birthplace of HIV
[1,29], which suggested the difficulty of implementing
HIV vaccines in this region.
Limitations and future perspectives
The limited number of full-length genomic sequences
for HIV-1 subtypes H, J and K, group P and HIV-2
group B (n < 10) may have affected our estimation of se-
quence diversity, but consistent patterns were detected
in the full-length genome across different HIV groupsand subtypes (Figure 2). Sequence diversity investiga-
tions at a population level for such clades may improve
when adding more sequences from individual proteins.
However, it would also result in difficulties (e.g. lack of
patient or treatment information) that may affect our
confidence in data quality, and consequently the accur-
acy of our results. Our structural analysis focuses on
HIV-1 proteins because most PDB data are available for
HIV-1 but not for HIV-2 (Additional file 2: Table S5).
Beside the multiple factors described in our study, other
driving forces may shape HIV genetic diversity [25,47]
and the genetic diversity data reported in our study can
be useful for further investigations. Information on po-
sitions involved in HIV-human protein interactions is
largely lacking, restricting our analysis from exploring
the genetic diversity of protein interaction positions.
Despite an extensive search, anti-HIV peptide inhibi-
tors other than the ones described here may have been
developed, but major changes in our conclusions re-
garding the known peptide-derived regions are not ex-
pected. Future studies are still needed to clarify how
to improve vaccines and anti-HIV inhibitors based on
the information of HIV genomic diversity. The in-
creased knowledge of genome-wide diversity from our
study may contribute to a better rational design of
HIV vaccines and inhibitors.
Methods
HIV genomic sequence dataset
In August 2013, we retrieved 3607 nucleotide genomic se-
quences of major HIV-1 and HIV-2 clades (HIV-2 group
A and B, HIV-1 group N, O, P, subtype A1, B, C, D, F1, G,
H, J, K, CRF01_AE, CRF02_AG) from the HIV Los Ala-
mos database (www.hiv.lanl.gov/). HIV-1 subtype was de-
termined by the Rega [48] and COMET [49] subtyping
tools. The quality criteria for removing duplicates and se-
quences with hypermutations, stop codons, ambiguous
nucleotides or discordant subtype classification were de-
scribed in [9]. The sequence dataset that fulfilled the qual-
ity criteria comprised 2996 genomic sequences, sampled
from 1684 HIV-1 and 21 HIV-2 patients between 1982
and 2013. Information on genomic sequence datasets is
summarized in Table 1.
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MUSCLE [50]. Protein regions encoded by their re-
spective open reading frames (ORFs) were concatenated
according to the reference strains (HIV-1: HXB2, HIV-
2: BEN). For each HIV protein coding region, the trans-
lation of nucleotide to amino acid sequence alignments
was optimized by our nucleotide to amino acid align-
ment toolbox. This toolbox maximizes amino acid
matches, including in overlapping reading frames, based
on the BLOSUM62 substitution matrix. Sequence align-
ments were further curated using Seaview v4.3 [51]. To
show the alignment quality, we measured the percent-
ages of deletions and insertions in the multiple sequence
alignments (MSAs) of HIV genomes, which were less
than 1.31% in 16 individual HIV clades (Additional file
2: Table S6). Our alignment toolbox and genomic se-
quences are available in Additional file 3.
PDB, HIV-human protein interaction, CD4/CD8/antibody
epitope datasets
As of February 2014, we queried HIV PDB data from the
RCSB Protein Data Bank using sequence search; PDB
quality was then examined using PDBREPORT [52]
(Additional file 2: Table S5). We extracted HIV-human
protein interactions (interaction type: physical interaction)
from the NCBI HIV-1 human protein interaction database
[53]. From the HIV Los Alamos database (http://
www.hiv.lanl.gov/content/immunology/), we extracted the
human CD4 T cell and antibody epitopes in HIV-1. For
human CTL/CD8 T cell epitopes, we included the best-
defined CTL epitopes of the A-list described in [54] (Add-
itional file 2: Table S7).
HIV-derived peptide inhibitor dataset
HIV-derived peptide inhibitors have their amino acid se-
quences derived from HIV proteins. We searched for Eng-
lish articles in PubMed published between January 1983 and
September 2013 using the keywords “HIV peptide inhibitor”,
“HIV [protein name] peptide” and “HIV [protein name] in-
hibitor”. References from primary studies, review articles
and peptide design papers were also reviewed. If more than
one peptide inhibitor were reported in one publication, only
the most promising peptide inhibitors as indicated by the
abstract of articles were collected. If data on the same inhibi-
tors was reported by more than one publication, only the
latest results were retained. Additional file 2: Table S4
summarizes the 121 peptide inhibitors with corresponding
information on peptide sequences, peptide-derived regions,
target proteins, inhibitory activities and references.
Protein secondary structure
For HIV-1 proteins (Rev, GP41) whose crystalized struc-
tures are not fully resolved in the PDB data, we used the
sequence-based method PSIPRED V3.0 [55] to estimateprotein secondary structures. For the other HIV-1
proteins with available PDB data (Additional file 2:
Table S5), we assessed protein secondary structures
using both PSIPRED V3.0 [55] and 2Struc [56]. 2Struc
is a software platform which integrates 8 PDB-based
methods: DSSP_CONT, DSSP, KAKSI, PALSSE, P-SEA,
STICKS, STRIDE and XTLSSTR [56]. Alpha-helix,
beta-strand and random-coil structures were estimated
using the majority voting of above 9 methods. Predic-
tion similarities between these 9 methods are shown in
Additional file 1: Figure S23.
Protein intrinsic disorder
Protein disordered regions are exploited by the virus to
invade cellular host systems [30]; these regions are often
structurally unstable without their partner molecules
[57]. We estimated the intrinsically disordered struc-
tures of HIV-1 subtype B proteins using three software
packages: MetaPrDOS [57], VSL2P [58] and PreDisor-
der v1.1 [59]. A disorder score (a numerical value be-
tween 0 and 1) of each amino acid position was
estimated by 17 methods in these 3 software packages.
An amino acid position was estimated as intrinsically
disordered if its disorder score was above the cutoff
value of 0.5 [57-59]. The intrinsically disordered posi-
tions were identified based on the majority voting of 17
methods. Prediction similarities between these 17
methods are shown in Additional file 1: Figure S24.
Solvent accessible surface area
We estimated protein solvent accessible surface areas
(ASA) using Chimera V1.6.1 [60] (default parameters).
Provided with PDB data in Additional file 2: Table S5, we
calculated the ASA at each amino acid of all HIV-1 pro-
tein units. For each of the 20 amino acids, a distribution of
its ASA scores over 15 HIV-1 proteins was obtained and
the maximum ASA was identified therein. An amino acid
at a specific position was considered buried if its ASA was
lower than 25% of the maximum ASA for the correspond-
ing amino acid [61] (Additional file 2: Table S8).
Phylogenetic analysis
Our phylogenetic analysis was performed using 1384 nu-
cleotide genomic sequences of 14 HIV groups and pure
subtypes (thus excluding CRFs), obtained from the earliest
sampling time (one sequence per patient). To prepare the
alignment, we also removed ambiguous regions containing
multiple insertions, deletions and hypervariable positions
(HXB2 index: 1126-1182, 6866-7003, 7106-7154, 7773-7842,
7981-8032, 8897-9383). Maximum-likelihood phylogenetic
trees were obtained using the multi-threaded FastTree V2.1
[62]. Our software parameters were set to 100 bootstrap
replicates, the fully optimized GTR (generalized time-
reversible) model, the continuous gamma distribution and
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consensus phylogenetic tree with bootstrap supports
was obtained using the seqboot tool in Phylip V3.69
(http://evolution.genetics.washington.edu/phylip.html).Ratio of non-synonymous and synonymous rate (dN/dS)
Following the protocol described in [26], we performed the
dN/dS analysis for HIV-1 subtype B using 495 genomic
sequences sampled from different treatment-naïve patients.
We firstly constructed a maximum-likelihood phylogenetic
tree using FastTree V2.1 [62] (parameters: continuous
gamma distribution, generalized time-reversible (GTR)
model). Provided with the constructed phylogenetic tree
and the codon sequence dataset, we then applied HyPhy
V2.1.0 [63] to estimate the non-synonymous (dN) and syn-
onymous (dS) substitution rates. We employed the single
likelihood ancestor counting (SLAC) model with the opti-
mized GTR [63]. Ambiguous nucleotides were resolved by
averaging over all possible states for the ancestral sequence
reconstruction [63]. Statistical significance of dN/dS was
measured by the continuous extension of binomial distri-
butions [63]. The above procedure was also performed for
HIV-1 subtype A1, C and CRF01_AE genomes using our
sequence datasets (Additional file 2: Table S2).Quantification of sequence diversity
Sequence diversity was calculated based on the pairwise
nucleotide (NT) and amino acid (AA) comparisons [9,64].
When calculating the amino acid diversity of HIV genome,
we concatenated the amino acid sequences of 15 HIV
protein coding regions in the full-length genome.
Suppose the sequence dataset D contains L sequences
with N positions, genetic diversity at position n is cal-
culated by: GD Dnð Þ ¼ 1− 2L L−1ð Þ
XL
i¼1
XL
j¼iþ1
δ Dn;i ¼ Dn;j
 
,
where Dn,i is the NT or AA form of the position n
at the ith sequence in the dataset D, δ represents the
Kronecker symbol, δ(Dn,i = Dn,j) equals 1 if Dn,i is
identical to Dn,j; otherwise 0. Given the sequence
dataset D, intra-clade genetic diversity AGD(D) is
defined as the average genetic diversity of all positions:
AGD Dð Þ ¼ 1− 1N
XN
n¼1
2
L L−1ð Þ
XL
i¼1
XL
j¼iþ1
δ Dn;i ¼ Dn;j
 
:
Suppose two sequence datasets D1 and D2 aligned
with the same reference genome have the number
of sequences L1 and L2 respectively. The inter-clade
genetic diversity between D1 and D2 is defined as:
RGD D1;D2ð Þ ¼ 1− 1N
XN
n¼1
1
L1  L2
XL1
i¼1
XL2
j¼1
δ D1n;i ¼ D2n;j
 
.
Furthermore, only positions for which less than 20% of
sequences had gaps were considered and gaps were treatedas missing data. Intra- and inter-clade genetic diversity was
measured using one genomic sequence per patient, while
intra-patient diversity was calculated using more than one
genomic sequence sampled from individual patients. The
Mann–Whitney U test was performed to compare the dis-
tributions of genetic diversity and a significant difference
was identified if a p-value was lower than 0.05 [65]. Our
Matlab implementation of genomic diversity analysis is
available in Additional file 3.
Additional files
Additional file 1: Figures and tables. Figure S1. Gene maps and
protein structures of HIV-1 and HIV-2. Figure S2. Distribution plots of
nucleotide and AA diversity among HIV types, groups and subtypes.
Figure S3. Distribution plots of AA diversity between HIV-1 subtype B/C
and the other HIV groups/subtypes. Figure S4. Global distribution of
HIV-1 genomic diversity. Figure S5. AA diversity along the full-length HIV
genome. Figure S6. Global distribution of HIV-1 genomic diversity.
Figure S7. Average AA diversity of HIV-1 protein clusters and number of
HIV-human protein interactions. Figure S8. AA composition of HIV-1
subtype B genome, HIV-1 peptide-derived regions and sequences of
HIV-derived peptide inhibitors. Figure S9. Average AA diversity of
peptide-derived regions in HIV-1 subtype B. Figure S10. Solvent
accessible surface area of peptide-derived regions in the HIV-1 subtype B
genome. Figure S11. Protein intrinsic disorder scores of peptide-derived
regions in the HIV-1 subtype B genome. Figure S12. Protein structure of
the HIV-1 GP120-CD4-Fab 48d complex (PDB: 2B4C, 3U4E) and mapped
GP120 peptide-derived inhibitors. Figure S13. GP41 structure and
GP41-derived peptide inhibitors. Figure S14. HIV-1 Integrase tetramer
and Integrase-derived peptide inhibitors. Figure S15. HIV-1 RT structure
and RT-derived peptide inhibitors. Figure S16. HIV-1 Protease
homodimer structure and protease-derived peptide inhibitors.
Figure S17. HIV-1 Tat structure and Tat-derived peptide inhibitors.
Figure S18. HIV-1 Vpr structure and Vpr-derived peptides. Figure S19.
HIV-1 Rev tetramer structure and Rev-derived peptide inhibitors.
Figure S20. Structure of HIV-1 Capsid monomer and Capsid-derived
peptide inhibitors. Figure S21. HIV-1 Vif structure and Vif-derived peptide
inhibitors. Figure S22. Distribution plots of AA diversity between the
consensus and the circulating genomes, within circulating genomes.
Figure S23. Prediction similarities of the consensus and the 9 protein
secondary structure prediction methods. Figure S24. Prediction
similarities of the consensus and 17 methods for protein intrinsically
disorder prediction.
Additional file 2: Table S1. Average amino acid diversity of HIV
monomeric and multimeric proteins. Table S2. Summary of average
AA diversity, average dN, average dS and average dN/dS in the HIV-1
subtype A1, B, C and CRF 01_AE genomes. Table S3. Statistical of dN/dS,
dN and dS distributions in the monomeric and multimeric protein groups
of the HIV-1 subtype A1, B, C and CRF01_AE genomes. Table S4.
Summary of 121 peptide inhibitors derived from HIV-1 proteins.
Table S5. Summary of protein structures and PDB data for HIV-1 and
HIV-2 proteins. Table S6. Percentages of deletions and insertions in the
HIV-1 and HIV-2 full-length genomic sequence alignments. Table S7.
Summary of antibody, CD4+, CD8+ T cell epitope positions. Table S8.
Cutoffs for determining solvent exposed residues.
Additional file 3: Software. Our Matlab toolbox developed for data
visualization, genomic diversity analysis and HIV genomic alignment. Our
sequence datasets are also included.
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